Altogether, these results suggest that NRTUAs targeted the invasion of dendritic and other myeloid cells in the immunosuppressive tumor environments to trigger mechanisms that break tumor immune tolerance and awaken potent CD8+ T-cell immunity to established cancers. The gene discussed is CD8A; the disease is neoplasm.